AURINIA PHARMACEUTICALS INC (AUPH) Stock Fundamental Analysis
NASDAQ:AUPH - Nasdaq - CA05156V1022 - Common Stock - Currency: USD
Taking everything into account, AUPH scores 6 out of 10 in our fundamental rating. AUPH was compared to 559 industry peers in the Biotechnology industry. AUPH is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. AUPH is evaluated to be cheap and growing strongly. This does not happen too often! With these ratings, AUPH could be worth investigating further for value and growth investing!.
1. Profitability
1.1 Basic Checks
AUPH had positive earnings in the past year.
AUPH had a positive operating cash flow in the past year.
AUPH had negative earnings in 4 of the past 5 years.
In the past 5 years AUPH reported 4 times negative operating cash flow.
1.2 Ratios
AUPH has a Return On Assets of 7.89%. This is amongst the best in the industry. AUPH outperforms 94.10% of its industry peers.
AUPH's Return On Equity of 11.38% is amongst the best of the industry. AUPH outperforms 94.28% of its industry peers.
AUPH's Return On Invested Capital of 8.56% is amongst the best of the industry. AUPH outperforms 94.45% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 7.89% | ||
| ROE | 11.38% | ||
| ROIC | 8.56% |
ROA(3y)-12.06%
ROA(5y)-18.32%
ROE(3y)-15.27%
ROE(5y)-21.75%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin of AUPH (16.11%) is better than 94.28% of its industry peers.
Looking at the Operating Margin, with a value of 19.56%, AUPH belongs to the top of the industry, outperforming 95.35% of the companies in the same industry.
Looking at the Gross Margin, with a value of 88.24%, AUPH belongs to the top of the industry, outperforming 90.88% of the companies in the same industry.
In the last couple of years the Gross Margin of AUPH has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 19.56% | ||
| PM (TTM) | 16.11% | ||
| GM | 88.24% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.39%
GM growth 5YN/A
2. Health
2.1 Basic Checks
AUPH has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
AUPH has less shares outstanding than it did 1 year ago.
Compared to 5 years ago, AUPH has more shares outstanding
Compared to 1 year ago, AUPH has an improved debt to assets ratio.
2.2 Solvency
An Altman-Z score of 3.32 indicates that AUPH is not in any danger for bankruptcy at the moment.
With a decent Altman-Z score value of 3.32, AUPH is doing good in the industry, outperforming 74.24% of the companies in the same industry.
The Debt to FCF ratio of AUPH is 1.11, which is an excellent value as it means it would take AUPH, only 1.11 years of fcf income to pay off all of its debts.
AUPH has a better Debt to FCF ratio (1.11) than 94.81% of its industry peers.
A Debt/Equity ratio of 0.16 indicates that AUPH is not too dependend on debt financing.
AUPH has a worse Debt to Equity ratio (0.16) than 68.69% of its industry peers.
Even though the debt/equity ratio score it not favorable for AUPH, it has very limited outstanding debt, so we won't put too much weight on the DE evaluation.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.16 | ||
| Debt/FCF | 1.11 | ||
| Altman-Z | 3.32 |
ROIC/WACC1.04
WACC8.23%
2.3 Liquidity
A Current Ratio of 5.93 indicates that AUPH has no problem at all paying its short term obligations.
The Current ratio of AUPH (5.93) is better than 60.82% of its industry peers.
AUPH has a Quick Ratio of 5.26. This indicates that AUPH is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of AUPH (5.26) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.93 | ||
| Quick Ratio | 5.26 |
3. Growth
3.1 Past
AUPH shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 171.79%, which is quite impressive.
Looking at the last year, AUPH shows a very strong growth in Revenue. The Revenue has grown by 29.20%.
Measured over the past years, AUPH shows a very strong growth in Revenue. The Revenue has been growing by 279.17% on average per year.
EPS 1Y (TTM)171.79%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%633.33%
Revenue 1Y (TTM)29.2%
Revenue growth 3Y72.76%
Revenue growth 5Y279.17%
Sales Q2Q%24.18%
3.2 Future
Based on estimates for the next years, AUPH will show a very strong growth in Earnings Per Share. The EPS will grow by 71.70% on average per year.
The Revenue is expected to grow by 12.03% on average over the next years. This is quite good.
EPS Next Y580%
EPS Next 2Y196.94%
EPS Next 3Y131.64%
EPS Next 5Y71.7%
Revenue Next Year9.69%
Revenue Next 2Y13.92%
Revenue Next 3Y14.89%
Revenue Next 5Y12.03%
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
AUPH is valuated quite expensively with a Price/Earnings ratio of 29.48.
Based on the Price/Earnings ratio, AUPH is valued cheaply inside the industry as 94.28% of the companies are valued more expensively.
The average S&P500 Price/Earnings ratio is at 26.55. AUPH is around the same levels.
A Price/Forward Earnings ratio of 10.40 indicates a reasonable valuation of AUPH.
AUPH's Price/Forward Earnings ratio is rather cheap when compared to the industry. AUPH is cheaper than 96.06% of the companies in the same industry.
AUPH is valuated cheaply when we compare the Price/Forward Earnings ratio to 22.40, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 29.48 | ||
| Fwd PE | 10.4 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, AUPH is valued cheaply inside the industry as 97.50% of the companies are valued more expensively.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of AUPH indicates a rather cheap valuation: AUPH is cheaper than 94.81% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 17.43 | ||
| EV/EBITDA | 8.92 |
4.3 Compensation for Growth
AUPH's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as AUPH's earnings are expected to grow with 131.64% in the coming years.
PEG (NY)0.05
PEG (5Y)N/A
EPS Next 2Y196.94%
EPS Next 3Y131.64%
5. Dividend
5.1 Amount
No dividends for AUPH!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:AUPH (6/12/2025, 3:08:07 PM)
8.255
+0.17 (+2.04%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners41.89%
Inst Owner Change7.99%
Ins Owners1.92%
Ins Owner Change8.63%
Market Cap1.12B
Analysts81.67
Price Target10.34 (25.26%)
Short Float %8.96%
Short Ratio8.44
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)109.07%
Min EPS beat(2)56.86%
Max EPS beat(2)161.28%
EPS beat(4)4
Avg EPS beat(4)197.36%
Min EPS beat(4)17.69%
Max EPS beat(4)553.6%
EPS beat(8)7
Avg EPS beat(8)119.79%
EPS beat(12)10
Avg EPS beat(12)89.11%
EPS beat(16)13
Avg EPS beat(16)66.53%
Revenue beat(2)0
Avg Revenue beat(2)-1.28%
Min Revenue beat(2)-2.09%
Max Revenue beat(2)-0.48%
Revenue beat(4)2
Avg Revenue beat(4)3.61%
Min Revenue beat(4)-2.09%
Max Revenue beat(4)15.16%
Revenue beat(8)5
Avg Revenue beat(8)7.94%
Revenue beat(12)9
Avg Revenue beat(12)11.49%
Revenue beat(16)13
Avg Revenue beat(16)11.96%
PT rev (1m)1.67%
PT rev (3m)1.67%
EPS NQ rev (1m)35.19%
EPS NQ rev (3m)21.67%
EPS NY rev (1m)34.53%
EPS NY rev (3m)4.9%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-3.76%
Revenue NY rev (1m)0.25%
Revenue NY rev (3m)-1.45%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 29.48 | ||
| Fwd PE | 10.4 | ||
| P/S | 4.51 | ||
| P/FCF | 17.43 | ||
| P/OCF | 17.35 | ||
| P/B | 3.18 | ||
| P/tB | 3.22 | ||
| EV/EBITDA | 8.92 |
EPS(TTM)0.28
EY3.39%
EPS(NY)0.79
Fwd EY9.61%
FCF(TTM)0.47
FCFY5.74%
OCF(TTM)0.48
OCFY5.76%
SpS1.83
BVpS2.59
TBVpS2.56
PEG (NY)0.05
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 7.89% | ||
| ROE | 11.38% | ||
| ROCE | 11.08% | ||
| ROIC | 8.56% | ||
| ROICexc | 30.16% | ||
| ROICexgc | 31.21% | ||
| OM | 19.56% | ||
| PM (TTM) | 16.11% | ||
| GM | 88.24% | ||
| FCFM | 25.88% |
ROA(3y)-12.06%
ROA(5y)-18.32%
ROE(3y)-15.27%
ROE(5y)-21.75%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.39%
GM growth 5YN/A
F-Score8
Asset Turnover0.49
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.16 | ||
| Debt/FCF | 1.11 | ||
| Debt/EBITDA | 0.84 | ||
| Cap/Depr | 1.47% | ||
| Cap/Sales | 0.12% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 94.79% | ||
| Profit Quality | 160.62% | ||
| Current Ratio | 5.93 | ||
| Quick Ratio | 5.26 | ||
| Altman-Z | 3.32 |
F-Score8
WACC8.23%
ROIC/WACC1.04
Cap/Depr(3y)6.1%
Cap/Depr(5y)121.69%
Cap/Sales(3y)0.25%
Cap/Sales(5y)3.74%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)171.79%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%633.33%
EPS Next Y580%
EPS Next 2Y196.94%
EPS Next 3Y131.64%
EPS Next 5Y71.7%
Revenue 1Y (TTM)29.2%
Revenue growth 3Y72.76%
Revenue growth 5Y279.17%
Sales Q2Q%24.18%
Revenue Next Year9.69%
Revenue Next 2Y13.92%
Revenue Next 3Y14.89%
Revenue Next 5Y12.03%
EBIT growth 1Y170.43%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year6475.33%
EBIT Next 3Y383.48%
EBIT Next 5YN/A
FCF growth 1Y198.21%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y199.75%
OCF growth 3YN/A
OCF growth 5YN/A